
Suven Life Sciences to Present 7 CNS Pipeline Posters at Neuroscience 2026
Suven Life Sciences will present seven scientific posters at Neuroscience 2026 in Washington D.C., highlighting its Central Nervous System (CNS) drug discovery and development pipeline. The presentations will cover clinical and preclinical drug candidates targeting neurodegenerative and neuropsychiatric disorders, including Alzheimer's Disease, Schizophrenia, Parkinson's Disease, Narcolepsy, Sleep Disorders, and Major Depressive Disorder. The posters showcase progress on advanced candidates like SUVN-M8036, SUVN-I6107 (Tenaclidine), SUVN-L1101142, Samelisant, SUVN-N9503012, Ropanicant (SUVN-911), and Masupirdine (SUVN-502), with several in Phase 3 and Phase 2 clinical development. This participation underscores Suven's commitment to developing innovative therapies for unmet medical needs in CNS disorders.
Key Highlights
- Suven Life Sciences to present seven scientific posters at Neuroscience 2026.
- Presentations cover CNS drug discovery pipeline targeting neurodegenerative/neuropsychiatric disorders.
- Includes clinical and preclinical candidates for Alzheimer's, Parkinson's, Schizophrenia, and more.
- Highlights advanced drug candidates in Phase 3 and Phase 2 clinical development.
Price Impact
More from SUVEN